These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2850003)

  • 1. Inhibition of gastric H+/K+-ATPase by substituted imidazo[1,2-a]pyridines.
    Briving C; Andersson BM; Nordberg P; Wallmark B
    Biochim Biophys Acta; 1988 Dec; 946(2):185-92. PubMed ID: 2850003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (H+ + K+)-ATPase.
    Keeling DJ; Laing SM; Senn-Bilfinger J
    Biochem Pharmacol; 1988 Jun; 37(11):2231-6. PubMed ID: 2837231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase.
    Mendlein J; Sachs G
    J Biol Chem; 1990 Mar; 265(9):5030-6. PubMed ID: 2156860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiulcer agents. 5. Inhibition of gastric H+/K(+)-ATPase by substituted imidazo[1,2-a]pyridines and related analogues and its implication in modeling the high affinity potassium ion binding site of the gastric proton pump enzyme.
    Kaminski JJ; Wallmark B; Briving C; Andersson BM
    J Med Chem; 1991 Feb; 34(2):533-41. PubMed ID: 1847427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole.
    Wallmark B; Briving C; Fryklund J; Munson K; Jackson R; Mendlein J; Rabon E; Sachs G
    J Biol Chem; 1987 Feb; 262(5):2077-84. PubMed ID: 3029064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.
    Keeling DJ; Malcolm RC; Laing SM; Ife RJ; Leach CA
    Biochem Pharmacol; 1991 Jun; 42(1):123-30. PubMed ID: 1648919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cl- channel in hog gastric vesicles is part of the function of H,K-ATPase.
    Asano S; Inoie M; Takeguchi N
    J Biol Chem; 1987 Sep; 262(27):13263-8. PubMed ID: 2443490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.
    Gedda K; Briving C; Svensson K; Maxvall I; Andersson K
    Biochem Pharmacol; 2007 Jan; 73(2):198-205. PubMed ID: 17081503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.
    Scott CK; Sundell E; Castrovilly L
    Biochem Pharmacol; 1987 Jan; 36(1):97-104. PubMed ID: 3026407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCH28080 prevents omeprazole inhibition of the gastric H+/K+-ATPase.
    Hersey SJ; Steiner L; Mendlein J; Rabon E; Sachs G
    Biochim Biophys Acta; 1988 Aug; 956(1):49-57. PubMed ID: 2841979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
    Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of gastric antisecretory effect of SCH 28080.
    Beil W; Hackbarth I; Sewing KF
    Br J Pharmacol; 1986 May; 88(1):19-23. PubMed ID: 3011171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the K+-competitive inhibitor site of gastric H,K-ATPase.
    Vagin O; Munson K; Lambrecht N; Karlish SJ; Sachs G
    Biochemistry; 2001 Jun; 40(25):7480-90. PubMed ID: 11412101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of H+,K+-ATPase by a K+-competitive photoaffinity inhibitor.
    Munson KB; Sachs G
    Biochemistry; 1988 May; 27(11):3932-8. PubMed ID: 2843221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pH on the interaction of ligands with the (H+ + K+)-ATPase purified from pig gastric mucosa.
    Ljungström M; Vega FV; Mårdh S
    Biochim Biophys Acta; 1984 Jan; 769(1):220-30. PubMed ID: 6318823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of gastric (H+ + K+)-ATPase by the substituted benzimidazole, picoprazole.
    Wallmark B; Sachs G; Mardh S; Fellenius E
    Biochim Biophys Acta; 1983 Feb; 728(1):31-8. PubMed ID: 6299338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
    Morii M; Takata H; Fujisaki H; Takeguchi N
    Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A substituted thieno[3.4-d]imidazole versus substituted benzimidazoles as H+, K+-ATPase inhibitors.
    Herling AW; Bickel M; Lang HJ; Weidmann K; Rösner M; Metzger H; Rippel R; Nimmesgern H; Scheunemann KH
    Pharmacology; 1988; 36(5):289-97. PubMed ID: 2841691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of putative SCH 28080 binding sites of the gastric H+,K+-ATPase.
    Asano S; Matsuda S; Tega Y; Shimizu K; Sakamoto S; Takeguchi N
    J Biol Chem; 1997 Jul; 272(28):17668-74. PubMed ID: 9211917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+ + K+)-ATPase.
    Keeling DJ; Taylor AG; Schudt C
    J Biol Chem; 1989 Apr; 264(10):5545-51. PubMed ID: 2538422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.